Publication:
Targeting NLRP3 (Nucleotide-Binding Domain, Leucine-Rich-Containing Family, Pyrin Domain-Containing-3) Inflammasome in Cardiovascular Disorders.

dc.contributor.authorWang, Zheng
dc.contributor.authorHu, Wei
dc.contributor.authorLu, Chenxi
dc.contributor.authorMa, Zhiqiang
dc.contributor.authorJiang, Shuai
dc.contributor.authorGu, Chunhu
dc.contributor.authorAcuña-Castroviejo, Darío
dc.contributor.authorYang, Yang
dc.date.accessioned2023-01-25T10:26:44Z
dc.date.available2023-01-25T10:26:44Z
dc.date.issued2018
dc.description.abstractInflammation is an important innate immune response to infection or tissue damage. Inflammasomes are involved in the onset and development of inflammation. The NLRP3 (nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3) inflammasome is the best-characterized inflammasome. Recent evidence has indicated the importance of the NLRP3 inflammasome in the pathophysiology of cardiovascular disorders. To further understand the roles of the NLRP3 inflammasome in the cardiovascular system, we provide a comprehensive overview and discuss the remaining questions. First, a summary of NLRP3 inflammasome in the cardiovascular system is introduced. Then, the associations between NLRP3 inflammasome and cardiovascular disorders are presented. Finally, we discuss existing problems and potential directions with this issue. The information compiled here summarizes recent progress, thus potentially aiding in the understanding of the NLRP3 inflammasome in cardiovascular disorders, designing experimental and clinical research about the NLRP3 inflammasome, and promoting therapeutics for cardiovascular disorders.
dc.identifier.doi10.1161/ATVBAHA.118.311916
dc.identifier.essn1524-4636
dc.identifier.pmid30571177
dc.identifier.unpaywallURLhttps://www.ahajournals.org/doi/pdf/10.1161/ATVBAHA.118.311916
dc.identifier.urihttp://hdl.handle.net/10668/13338
dc.issue.number12
dc.journal.titleArteriosclerosis, thrombosis, and vascular biology
dc.journal.titleabbreviationArterioscler Thromb Vasc Biol
dc.language.isoen
dc.organizationIBS
dc.page.number2765-2779
dc.pubmedtypeJournal Article
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.pubmedtypeReview
dc.rights.accessRightsopen access
dc.subjectatherosclerosis
dc.subjectcardiovascular diseases
dc.subjectinflammation
dc.subjectinterleukins
dc.subjectmyocardial ischemia
dc.subject.meshAnimals
dc.subject.meshAnti-Inflammatory Agents
dc.subject.meshCardiovascular Agents
dc.subject.meshCardiovascular Diseases
dc.subject.meshHumans
dc.subject.meshImmunity, Innate
dc.subject.meshInflammasomes
dc.subject.meshMolecular Targeted Therapy
dc.subject.meshNLR Family, Pyrin Domain-Containing 3 Protein
dc.subject.meshSignal Transduction
dc.titleTargeting NLRP3 (Nucleotide-Binding Domain, Leucine-Rich-Containing Family, Pyrin Domain-Containing-3) Inflammasome in Cardiovascular Disorders.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number38
dspace.entity.typePublication

Files